TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Score on attenuated negative symptom scale at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on adverse events rating scale at 12 weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Apgar Score below 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term tumor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: late treatment lung toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Gestational week at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Newborn birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: APGAR Score at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in Disease Activity by Harvey Bradshaw Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Disease Activity by Fecal Calprotectin (FCP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting Plasma Glucose Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting Plasma Insulin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetics of rifabutin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Consumption of Tramadol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain during active flexion of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reflux Symptom Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: air leak reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of relapses during intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean urination times (24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Major bleed
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of abnormalities on cardiac MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUClast of Filgotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of GS-829845
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of Filgotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of GS-829845
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Filgotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of GS-829845
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay of progression of Motor dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety of MVA85A vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Alkaline Phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of subjects avoiding 15 letters of best-corrected distance visual acuity loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 15 letter improvement of best-corrected distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast Cancer Risk
Endpoint domain: Mortality/survival
Primary endpoint: Mean Annual Rate of Respiratory Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intraocular pressure readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-concussion symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in HbA1C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: % of nipple areola complex conservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Hemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 3D-based Alveolar bone radiographic density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritability subscale of the Aberrant Behavior Checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioavailability of imatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetics of imatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-peptide area under the concentration curve (AUC) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall Survival (OS) Time in Months
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (OS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Deaths From Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive Therapy Scale (CTS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Primary Safety Endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in values from baseline electrophysiology study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Tolerated Dose level (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Local skin reactions and pigmentation and scarring
Endpoint domain: Adverse events/effects
Primary endpoint: Roland Morris Low Back Pain Disability Questionnaire (RMDQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Canine retraction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants recruited in the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average number of sessions attended by participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of patients who drop out of study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Satisfaction Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Endotracheal intubation or non-invasive ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of delivery prior to 37 weeks of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Hospital Admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Amputation Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Walking speed change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the Hamilton Depression Rating Scale (HAM-D) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objective tumour response (complete + partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical benefit (CR + PR + SD > 24 wks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of EBV or CMV Related Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time-to-Treatment Failure
Endpoint domain: Mortality/survival
Primary endpoint: Change in Glycosylated Hemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Dose Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Success Based on IGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Success Based on TLSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent-Reported Resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall tumor response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Subjects With Elevated MyxA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor regression response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Systemic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Ambulatory Care Sensitive Conditions (ACSC) Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Progression of Diabetic Retinopathy (DR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Severity of Diabetic Retinopathy (DR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Area-Under-the Concentration Curve from zero-to-twenty two hours (AUC,0-22) of Dasatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area-Under-the Concentration Curve from zero-to-infinity (AUC,0-inf) of Dasatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality at day 28
Endpoint domain: Mortality/survival
Primary endpoint: PANSS positive symptoms subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response rate for HIV related malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Forced Expiratory Volume in 1 second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in atrial wall stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of handheld calorimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suicidal ideation and behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self reported pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days per week participants performed foot inspection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life measurement: Visual Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life measurement: Neck Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of life measurement: Short Form Brief Pain Inventory
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of subjects with plasma HIV-1 RNA <400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial resistance or selection
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Suspected Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Dynamic changes of HBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dynamic changes of PAL-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patency of Saphenous Vein Grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Risk factors related to metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Major cerebrovascular and cardiac events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major gastrointestinal event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Annualised change in GFR (delta GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Inhibitory control performance, Task 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inhibitory control performance, Task 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inhibitory control neural activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Phenolic acids bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee flexion and extension Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Walked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Well-Being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA) of 20/20 or Better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Immune Recovery Following Transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence and Severity of GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Visual Numeric Scale (VNS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse effects during Dobutamine infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Ability of LDDE to predict outcome in patients with paradoxical low-flow, low-gradient aortic stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Perceived Stress Scale (PSS) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum Corrected Ca Concentration Under 10.3 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase of Absolute Neutrophil Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Stimulus-response function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successfully implant the WATCHMAN device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Absence of a composite of major complications
Endpoint domain: Adverse events/effects
Primary endpoint: Oxygen variation in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change of total score on the Clinical Assessment Interview for Negative Symptoms (CAINS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cessation of paroxysmal hypertension symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction of paroxysmal hypertension symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Viral etiologies of isolated fevers and influenza-like syndromes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement on ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: microvascular perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TFV plasma exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Matrix Metalloprotease-9 (MMP-9) Protein Levels in Sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of outpatient visits to medical doctor
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Registration of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in vital signs from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in lab parameters from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Functional Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Amount of total body water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extracellular to intracellular water ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical state as reflected by NEWS scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive PCR
Endpoint domain: Adverse events/effects
Primary endpoint: Pathological Gambling Adaptation of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of inpatient hospital encounters
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rivermead Behavioural Memory Test (RBMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Frontal Assessment Battery (FAB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Symbol Digit Modalities Test (SDMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Healthy Lifestyle Behavior Scale-II
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: General Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients achieving Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Depression Assessment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change From Baseline in Bone Mineral Density (BMD) at Total Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pulmonary Function Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects who survive EVD
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Isthmocele Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of fMRI and MEG in pre-operative brain mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in cholesterol efflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from the baseline in High-Density Lipoprotein Cholesterol (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in ISGA Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bone Formation Rate (BFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: number of rehospitalisations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: health personnel's opinion on patient safety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average Oxygen Saturation by Pulse Oximetry (SpO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Awakening From Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suspension Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: intraindividual variation in reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adenoma Detection Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diaphragmatic amplitude in wide breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Proteinuria Levels at Week 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Anti-phospholipase A2 Receptor (PLA2R) Autoantibody Titers at Week 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of autologous transduced T-lymphocytes with functional γc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of serious side effects due to lentiviral gene transfer
Endpoint domain: Adverse events/effects
Primary endpoint: Distribution of integration sites of the lentiviral vector in reconstituted peripheral blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood orphanin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes